Peer-reviewed veterinary case report
New chewable tablet Credelio Quattro treats dog gut worms safely
By Samuel Charles et al.·Published in Parasites & Vectors·2025·Elanco Animal Health, GB·View original on DOAJ →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Field efficacy and safety evaluation of a novel chewable tablet (Credelio Quattro™) containing lotilaner, moxidectin, praziquantel, and pyrantel against gastrointestinal nematode infections in dogs in the USA
- Species:
- dog
Plain-English summary
A group of dogs with gastrointestinal worm infections, specifically hookworms and roundworms, were treated with a new chewable tablet called Credelio Quattro. This treatment was shown to be highly effective, reducing hookworm eggs in feces by 99.9% and roundworm eggs by nearly 99% within 10 days. While some dogs experienced mild side effects like diarrhea and lethargy, the overall safety and effectiveness of the medication were confirmed. This new treatment could be a good option for pet owners looking to manage these common parasites in their dogs.
People also search for: dog hookworm treatment · roundworm symptoms in dogs · Credelio Quattro side effects
Abstract
Abstract Background Gastrointestinal nematodes such as hookworms (Ancylostoma caninum) and roundworms (Toxocara canis) commonly infect dogs and are zoonotic parasites capable of producing clinical disease in humans. This field study was conducted to confirm the clinical effectiveness and field safety of a novel, chewable tablet (Credelio Quattro™) containing lotilaner, moxidectin, praziquantel, and pyrantel (as pamoate salt) as compared with a control product containing sarolaner, moxidectin, and pyrantel (as pamoate salt) for the treatment of naturally occurring gastrointestinal nematode infections in dogs. Methods In this multicenter field study, 158 dogs were enrolled with an evaluable safety population of 155 dogs and an evaluable effectiveness population of 109 dogs. Dogs were randomized in a 2:1 ratio to receive either the investigational veterinary product (IVP) Credelio Quattro containing lotilaner, moxidectin, praziquantel, and pyrantel or the control product (CP) containing sarolaner, moxidectin, and pyrantel. On Day 0, after confirmation of infection, enrolled dogs were randomized, dispensed, and administered IVP or CP. Enrolled dogs returned to the study site on Day 10 (± 2 d) to quantify the concentration of nematode eggs post-treatment. Results Post-treatment fecal egg counts performed on Day 10 demonstrated a 99.9% reduction in A. caninum eggs per gram in both IVP-treated dogs and CP-treated dogs. In addition, a 98.7% and 96.6% reduction in T. canis fecal egg counts were observed in IVP- and CP-treated dogs, respectively. Adverse events were reported in both treatment groups. The most common adverse events reported in the IVP group included gastrointestinal signs, such as diarrhea and emesis, as well as lethargy. Conclusions This field study demonstrated that Credelio Quattro, a novel oral combination chewable tablet administered at the labeled dose ranges of 20–40 mg/kg lotilaner, 0.02–0.04 mg/kg moxidectin, 5–10 mg/kg praziquantel, and 5–10 mg/kg pyrantel (as pamoate salt), is safe and effective for the treatment and control of naturally occurring A. caninum and T. canis infections in dogs. Graphical Abstract
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on DOAJ: https://doi.org/10.1186/s13071-025-06932-7